Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00003731
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors.
- Detailed Description
OBJECTIVES: I. Assess the therapeutic activity of temozolomide as first line chemotherapy in patients with recurrent oligodendroglial tumors after radiation therapy. II. Assess the objective response and duration of response of these patients given this treatment. III. Characterize the acute side effects of temozolomide in this patient population.
OUTLINE: This is an open label, multicenter study. Patients receive oral temozolomide on days 1-5. Courses are repeated every 28 days. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 15-33 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (24)
Hopital Universitaire Erasme
🇧🇪Brussels, Belgium
Academisch Ziekenhuis der Vrije Universiteit Brussel
🇧🇪Brussels, Belgium
U.Z. Gasthuisberg
🇧🇪Leuven, Belgium
Centre Hospitalier Regional de Lille
🇫🇷Lille, France
CHU de la Timone
🇫🇷Marseille, France
CHU de Nancy - Hopital Neurologique
🇫🇷Nancy, France
Hopital Pasteur
🇫🇷Nice, France
Centre Antoine Lacassagne
🇫🇷Nice, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Nervenklinik Bamberg
🇩🇪Bamberg, Germany
Scroll for more (14 remaining)Hopital Universitaire Erasme🇧🇪Brussels, Belgium